Apyx Medical (APYX) Names Stavros Vizirgianakis Executive Chairman

This summary was generated by AI from the company's SEC filing and may contain errors — always verify against the primary source on SEC.gov.

The short version

Apyx Medical Corp (APYX) appointed Stavros Vizirgianakis as Executive Chairman effective June 11, 2026, according to an 8-K filing (a report companies use to disclose major news) filed June 17, 2026. As compensation, he received a grant of 450,000 restricted stock units (RSUs — a promise to deliver company shares over time), with no cash salary attached to the role. The RSUs vest in three equal tranches of 150,000 over roughly three years, and all unvested RSUs would immediately vest if someone acquires control of the company.

Apyx Medical Corp (APYX) has appointed Stavros Vizirgianakis as Executive Chairman of its Board of Directors, effective June 11, 2026, the company said in a filing with the U.S. Securities and Exchange Commission.

Vizirgianakis was already serving as a board member. His new role adds executive responsibilities on top of that existing seat, including providing strategic direction, helping management execute company initiatives, supporting fundraising efforts, and advising on investor relations and corporate development, according to the filing.

Pay: Stock Only, No Cash

Apyx Medical said Vizirgianakis will receive no cash salary for the Executive Chairman role. Instead, the company granted him 450,000 RSUs (restricted stock units — a form of compensation that converts into real company shares once certain conditions are met) under its 2023 Share Incentive Plan. The grant was made on June 11, 2026, subject to Board approval.

How the Shares Vest

The 450,000 RSUs are split into three equal portions of 150,000:

150,000 RSUs vested immediately on June 11, 2026 (the grant date).
150,000 RSUs begin vesting on the first anniversary of the grant date (June 11, 2027) and then vest in equal monthly installments over the following 12 months.
150,000 RSUs begin vesting on the second anniversary of the grant date (June 11, 2028) and then vest in equal monthly installments over the following 12 months.

If Vizirgianakis leaves the role before any RSUs have vested, those unvested units are forfeited — meaning he would not receive the shares.

Change-of-Control Provision

The filing includes a clause stating that if a "change of control" occurs — broadly defined as someone acquiring more than 50% of the company's voting power, a merger where existing shareholders end up as a minority, or a sale of substantially all company assets — all remaining unvested RSUs would immediately vest in full just before the deal closes.

Background

The agreement was signed by CEO Charlie Goodwin on behalf of Apyx Medical and countersigned by Vizirgianakis. The company is headquartered at 5115 Ulmerton Road, Clearwater, Florida.

Key facts

Apyx Medical Corp (APYX, CIK 0000719135) appointed Stavros Vizirgianakis as Executive Chairman effective June 11, 2026.

Vizirgianakis was already a member of the Apyx Medical Board of Directors.

He will receive no cash compensation for the Executive Chairman role.

He was granted 450,000 RSUs (restricted stock units) under the company's 2023 Share Incentive Plan.

150,000 RSUs vested immediately on June 11, 2026; 150,000 vest monthly starting June 11, 2027; 150,000 vest monthly starting June 11, 2028.

All unvested RSUs accelerate and vest immediately upon a change of control (acquisition of >50% voting power, qualifying merger, or sale of substantially all assets).

The agreement was signed by CEO Charlie Goodwin on behalf of Apyx Medical.

The 8-K was filed June 17, 2026.

Why it matters

The appointment of an Executive Chairman — a board-level role with active strategic duties — alongside a 450,000-RSU grant signals that Apyx Medical is adding senior executive bandwidth without increasing its cash cost base. The full-acceleration change-of-control clause is notable: it means any acquirer would need to account for the immediate vesting of all remaining shares granted to Vizirgianakis. That provision is common in executive agreements but can be relevant if the company is ever involved in a transaction. Investors should note this is an equity-based compensation arrangement, meaning the RSUs will dilute existing shareholders as shares are delivered over time.

Frequently asked

What is Stavros Vizirgianakis's new role at Apyx Medical?

He was appointed Executive Chairman of Apyx Medical's Board of Directors, effective June 11, 2026. He was already serving as a regular board member, and this new title adds executive responsibilities such as strategic leadership and helping with fundraising and investor relations.

How much is Stavros Vizirgianakis being paid as Executive Chairman?

He will receive no cash salary. His only compensation for the role is a grant of 450,000 RSUs (restricted stock units), which convert into Apyx Medical shares as they vest over roughly three years.

What happens to the RSUs if Apyx Medical is acquired?

According to the filing, all unvested RSUs would immediately vest in full just before a qualifying change of control closes — for example, if someone acquires more than 50% of Apyx Medical's voting power or the company is sold.

What is the RSU vesting schedule?

The 450,000 RSUs are split into three equal groups of 150,000. The first 150,000 vested immediately on June 11, 2026. The second 150,000 begin vesting monthly starting June 11, 2027, spread equally over 12 months. The third 150,000 begin vesting monthly starting June 11, 2028, also spread equally over 12 months.

What the filing reported

1.01 Entry into a Material Agreement

9.01 Financial Statements & Exhibits